Schizophrenia research grapples with trial design hurdles in hunt for new treatments
A sector plagued by drug failures is looking to optimise study methodology, site selection, and patient recruitment.
Therapy Area
Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine
ArriVent’s stock plummets on Phase III NSCLC trial failure
ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial
Parkinson’s disease market expected to reach $7.2bn across the 7MM by 2033
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
